We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M Turnover 22.92%
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+15.25%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$126M
AUM Growth
+$10.2M
Cap. Flow
-$1.82M
Cap. Flow %
-1.44%
Top 10 Hldgs %
41.21%
Holding
109
New
16
Increased
15
Reduced
23
Closed
15
Avg Time Held
1 year
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
1 year

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$2.72M
2
SYRE icon
Spyre Therapeutics
SYRE
+$2.69M
3
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$2.28M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$2.22M
5
LOXO
Loxo Oncology, Inc
LOXO
+$1.57M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$2.45M
2
MRNS icon
Marinus Pharmaceuticals, Inc
MRNS
+$2.19M
3
BEAT icon
BioTelemetry, Inc.
BEAT
+$2M
4
MASI icon
Masimo
MASI
+$1.7M
5
CYAD
Celyad Oncology SA American Depositary Shares
CYAD
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 84.52%
2 Miscellaneous 15.38%
3 Technology 0.1%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MGNX icon
26
MacroGenics
MGNX
$207M
$1.46M 1.16%
54,200
– –
2015 Q3
3 quarters
CYTK icon
27
Cytokinetics
CYTK
$8.61B
$1.42M 1.13%
150,000
+94,400
+170% +$775K
2015 Q4
2 quarters
DSCI
28
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.39M 1.1%
353,718
– –
2013 Q2
12 quarters
RDUS icon
29
DELISTED
Radius Health, Inc.
RDUS
$1.38M 1.1%
37,600
-5,000
-12% -$177K
2016 Q1
1 quarter
STXS icon
30
Stereotaxis
STXS
$101M
$1.34M 1.07%
1,372,862
– –
2013 Q2
12 quarters
TVRD icon
31
Tvardi Therapeutics
TVRD
$13.5M
$1.28M 1.02%
7,418
– –
2015 Q2
4 quarters
XENE icon
32
Xenon Pharmaceuticals
XENE
$3.24B
$1.26M 1%
214,091
+20,896
+11% +$143K
2015 Q3
3 quarters
FOMX
33
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.22M 0.97%
192,567
+73,896
+62% +$490K
2015 Q4
2 quarters
RGLS icon
34
DELISTED
Regulus Therapeutics
RGLS
$1.22M 0.97%
3,513
+250
+8% +$179K
2015 Q3
3 quarters
SGYP
35
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.21M 0.96%
319,563
+25,000
+8% +$84.7K
2015 Q2
4 quarters
CRBP icon
36
Corbus Pharmaceuticals
CRBP
$87.4M
$1.2M 0.95%
+13,333
New +$1.05M
2016 Q2
0 quarters
AKAO
37
DELISTED
Achaogen Inc
AKAO
$1.19M 0.94%
+314,341
New +$1.09M
2016 Q2
0 quarters
QURE icon
38
uniQure
QURE
$1.51B
$1.17M 0.93%
158,907
– –
2014 Q3
7 quarters
JNJ icon
39
Johnson & Johnson
JNJ
$616B
$1.14M 0.9%
9,400
– –
2013 Q2
12 quarters
LDRH icon
40
DELISTED
LDR HOLDINGS CORP COM STK
LDRH
$1.11M 0.88%
30,000
-20,300
-40% -$576K
2016 Q1
1 quarter
WINT icon
41
DELISTED
Windtree Therapeutics Inc
WINT
$1.03M 0.82%
533,358
– –
2013 Q2
12 quarters
NVDQ icon
42
DELISTED
Novadaq Technologies Inc.
NVDQ
$1M 0.79%
101,841
– –
2013 Q2
12 quarters
EXAC
43
DELISTED
Exactech Inc
EXAC
$846K 0.67%
31,636
– –
2013 Q2
12 quarters
NERV icon
44
Minerva Neurosciences
NERV
$112M
$818K 0.65%
+10,013
New +$637K
2016 Q2
0 quarters
EPIX icon
45
DELISTED
ESSA Pharma
EPIX
$810K 0.64%
10,125
– –
2015 Q3
3 quarters
GERN icon
46
Geron
GERN
$752M
$764K 0.61%
+285,000
New +$829K
2016 Q2
0 quarters
CNCE
47
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$752K 0.6%
+66,968
New +$853K
2016 Q2
0 quarters
ASND icon
48
Ascendis Pharma A/S
ASND
$14.8B
$707K 0.56%
53,241
– –
2015 Q1
5 quarters
ELOS
49
DELISTED
Syneron Medical Ltd
ELOS
$661K 0.52%
85,947
– –
2013 Q2
12 quarters
ONC icon
50
BeOne Medicines Ltd
ONC
$41.7B
$596K 0.47%
20,000
– –
2016 Q1
1 quarter
1
2
3 4 5

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, DAFNA Capital Management held 109 positions worth $126M, up 8.8% from $116M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

DAFNA Capital Management's Q2 2016 filing shows 16 new, 15 increased, 23 reduced and 15 closed positions. Its largest new stake was Immunomedics Inc: 815,000 shares worth $1.89M. The largest sale was AbbVie, an estimated $2.45M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Technology.

  • DAFNA Capital Management's largest Q2 2016 buy was Immunomedics Inc: 815,000 shares worth $1.89M.
  • DAFNA Capital Management added most to CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q2 2016, an estimated $2.28M increase.
  • DAFNA Capital Management's biggest Q2 2016 reduction was AbbVie, cutting an estimated $2.45M.
  • DAFNA Capital Management fully exited Celyad Oncology SA American Depositary Shares in Q2 2016, selling an estimated $1.32M.
  • DAFNA Capital Management's ten largest holdings make up 41% of its $126M portfolio in Q2 2016.
  • DAFNA Capital Management opened 16 new positions and closed 15 in Q2 2016.
  • DAFNA Capital Management's portfolio value rose 8.8% quarter-over-quarter to $126M.

Based on DAFNA Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.